Patents by Inventor James Vornov
James Vornov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230257363Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: ApplicationFiled: September 23, 2022Publication date: August 17, 2023Inventors: Reza Mazhari, Djelila Mezaache, Blake M Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Patent number: 11479542Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: GrantFiled: May 27, 2020Date of Patent: October 25, 2022Assignees: CERECOR, INC., MERCK SHARP & DOHME CORP.Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Patent number: 11331271Abstract: Methods for buccally, sublingually, or intranasally administering a prodrug of propofol to a subject in need of treatment thereof in an amount sufficient to deliver a therapeutically effective amount of propofol to the subject are disclosed.Type: GrantFiled: May 25, 2017Date of Patent: May 17, 2022Assignee: The Johns Hopkins UniversityInventors: Barbara Slusher, Rana Rais, James Vornov
-
Publication number: 20210107892Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: ApplicationFiled: May 27, 2020Publication date: April 15, 2021Inventors: Reza Mazhari, Ojelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Publication number: 20200289404Abstract: Methods for buccally, sublingually, or intranasally administering a prodrug of propofol to a subject in need of treatment thereof in an amount sufficient to deliver a therapeutically effective amount of propofol to the subject are disclosed.Type: ApplicationFiled: May 25, 2017Publication date: September 17, 2020Inventors: Barbara Slusher, Rana Rais, James Vornov
-
Patent number: 10710976Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: GrantFiled: February 11, 2019Date of Patent: July 14, 2020Assignees: Cerecor Inc., Merck Sharp & Dohme Corp.Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Publication number: 20190177299Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: ApplicationFiled: February 11, 2019Publication date: June 13, 2019Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Patent number: 10202363Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: GrantFiled: December 18, 2015Date of Patent: February 12, 2019Assignees: CERECOR, INC., MERCK SHARP & DOHME CORP.Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Publication number: 20170369469Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.Type: ApplicationFiled: December 18, 2015Publication date: December 28, 2017Applicants: Cerecor, Inc., Merck Sharp & Dohme Corp.Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
-
Publication number: 20050203068Abstract: The present invention is directed to pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering the prodrug. In one aspect, a method of inducing and/or maintaining a generalized anesthetic state comprises administering by parenteral infusion a prodrug of propofol in an amount sufficient to cause and/or maintain loss of consciousness. In another aspect, a prodrug of propofol is administered for producing a sedated state in a subject.Type: ApplicationFiled: April 8, 2003Publication date: September 15, 2005Inventors: Peggy Wingard, Eric Burak, Ekaterina Gibiansky, James Vornov